February 2017 – The CenterWatch Monthly : PDF
Reassessing site engagement activities
Drug development sponsors and CROs increasingly recognize the importance of investigative sites having a stronger, more respected voice in the clinical research community and have begun adopting initiatives designed to incorporate site viewpoints into improving clinical development processes.
The need for—and barriers to—adopting eSource
Electronic data collection responsibility borne by investigative sites to support each clinical trial is onerous, with little to no relief in sight. In many instances, these responsibilities are being managed at the same time that paper data collection processes are prevalent.
Also in this issue:
- Identifying opportunities in emerging markets
- A new era of clinical trial patient identification
- Regulatory Update
- Month in Review
- FDA Actions
- Study Lead Opportunities
- New Drugs in the Pipeline